Recommendations for use of meningococcal conjugate vaccines in HIV-infected persons - Advisory committee on immunization practices, 2016

Morbidity and Mortality Weekly Report

Volumn 65, Issue 43, 2016, Pages 1189-1194

  MacNeil, Jessica R ^a   Rubin, Lorry G ^b,c,d   Patton, Monica ^a   Ortega Sanchez, Ismael R ^a   Martin, Stacey W ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b Advisory Committee on Immunization Practices Meningococcal Vaccines Work Group   (United States)

^c Northwell Health   (United States)

^d DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MENINGOCOCCUS VACCINE; VACCINE;

ADOLESCENT; ADULT; ADVISORY COMMITTEE; CHILD; FEMALE; HIV INFECTIONS; HUMAN; IMMUNIZATION; INFANT; MALE; MENINGOCOCCAL INFECTIONS; MIDDLE AGED; PRACTICE GUIDELINE; PRESCHOOL CHILD; PUBLIC HEALTH SERVICE; RISK ASSESSMENT; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; ADVISORY COMMITTEES; CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); CHILD; CHILD, PRESCHOOL; FEMALE; HIV INFECTIONS; HUMANS; IMMUNIZATION SCHEDULE; INFANT; MALE; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; UNITED STATES; VACCINES, CONJUGATE; YOUNG ADULT;

EID: 84995483244     PISSN: 01492195     EISSN: 1545861X     Source Type: Journal    
DOI: 10.15585/mmwr.mm6543a3     Document Type: Article

References (16)

1. Cohn AC, MacNeil JR, Clark TA, et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013 (No. RR-2).
2. Lujan-Zilbermann J, Warshaw MG, Williams PL, et al. Immunogenicity and safety of 1 vs 2 doses of quadrivalent meningococcal conjugate vaccine in youth infected with human immunodeficiency virus. J Pediatr 2012;161: 676-81.e2.
3. Siberry GK, Warshaw MG, Williams PL, et al. Safety and immunogenicity of quadrivalent meningococcal conjugate vaccine in 2- to 10-year-old human immunodeficiency virus-infected children. Pediatr Infect Dis J 2012;31: 47-52. http://dx.doi.org/10.1097/INF.0b013e318236c67b
4. Siberry GK, Williams PL, Lujan-Zilbermann J, et al. Phase I/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents. Pediatr Infect Dis J 2010;29: 391-6. http://dx.doi.org/10.1097/INF.0b013e3181c38f3b
5. Schuchat A, Hilger T, Zell E, et al. Active bacterial core surveillance of the emerging infections program network. Emerg Infect Dis 2001;7: 92-9. http://dx.doi.org/10.3201/eid0701.010114
6. Cohen C, Singh E, Wu HM, et al. Increased incidence of meningococcal disease in HIV-infected individuals associated with higher case-fatality ratios in South Africa. AIDS 2010;24: 1351-60. http://dx.doi.org/10.1097/QAD.0b013e32833a2520
7. Miller L, Arakaki L, Ramautar A, et al. Elevated risk for invasive meningococcal disease among persons with HIV. Ann Intern Med 2014;160: 30-7. http://dx.doi.org/10.7326/0003-4819-160-1-201401070-00731
8. Simmons RD, Kirwan P, Beebeejaun K, et al. Risk of invasive meningococcal disease in children and adults with HIV in England: a population-based cohort study. BMC Med 2015;13: 297. http://dx.doi.org/10.1186/s12916-015-0538-6
9. Harris CM, Wu HM, Li J, et al. Meningococcal disease in patients with HIV infection-a review of cases reported through active surveillance in the United States, 2000-2008. Open Forum Infect Dis 2016. Epub October 24, 2016. http://ofid.oxfordjournals.org/content/early/2016/10/24/ofid.ofw226.full.pdf+html
10. MacNeil JR, Rubin L, McNamara L, Briere EC, Clark TA, Cohn AC. Use of MenACWY-CRM vaccine in children aged 2 through 23 months at increased risk for meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2013. MMWR Morb Mortal Wkly Rep 2014;63: 527-30.
11. CDC. Licensure of a meningococcal conjugate vaccine for children aged 2 through 10 years and updated booster dose guidance for adolescents and other persons at increased risk for meningococcal disease-Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011;60: 1018-9.
12. CDC. Recommendation of the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MenACWY-D) among children aged 9 through 23 months at increased risk for invasive meningococcal disease. MMWR Morb Mortal Wkly Rep 2011;60: 1391-2.
13. Food and Drug Administration. Menveo U.S. package insert. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2013. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM201349.pdf
14. Klein NP, Reisinger KS, Johnston W, et al. Safety and immunogenicity of a novel quadrivalent meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infants. Pediatr Infect Dis J 2012;31: 64-71. http://dx.doi.org/10.1097/INF.0b013e31823dce5c
15. Nolan TM, Nissen MD, Naz A, et al. Immunogenicity and safety of a CRM-conjugated meningococcal ACWY vaccine administered concomitantly with routine vaccines starting at 2 months of age. Hum Vaccin Immunother 2014;10: 280-9. http://dx.doi.org/10.4161/hv.27051
16. Food and Drug Administration. Menactra U.S. package insert. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2016. http://www.fda.gov/downloads/BiologicBloodVaccines/Vaccines/ApprovedProducts/UCM131170.pdf